The Lymphatic Malformation Institute (LMI) was established in December, 2010, and is focused, as a whole, on advancing the understanding of the lymphatic system and, specifically, advancing the understanding of the complex lymphatic anomalies (CLAs), including Generalized lymphatic anomaly (GLA)/Lymphangiomatosis, Gorham-Stout disease (GSD), Kaposiform lymphangiomatosis (KLA), and Central Conducting lymphatic anomaly (CCLA).
The goal of the LMI is to find cures and treatments for these life-threatening disorders that have received very little attention from the scientific community in the past. The LMI seeks to fill this critical gap by identifying, organizing and funding research studies by medical and research professionals, and also working closely with other foundations with similar objectives.
The LMI’s focused strategy includes the following initiatives:
- Identify, fund and systematically monitor research projects that further our understanding of lymphatic biology, especially as it relates to GLA, GSD, KLA, and CCLA.
- Support development and sharing of laboratory tools and reagents critical to conducting research.
- Fund and monitor the progress of clinical trials, new treatments and medications that may help to treat the many complications that can arise from lymphatic malformations.
- Promote and support a culture of collaboration and communication between medical professionals, research professionals, patient support groups and patients themselves in which all are put in the best position for beneficial outcomes.